StephenRobertMarderMD
Psychiatry • Los Angeles, CAProfessor at UCLA Director, Section on Psychosis - UCLA Neuropsychiatric Institute and Hospital Director, Section on Psychosis - UCLA Semel Institute Professor and Director, Section on Psychosis UCLA Semel Institute of Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA Director, MIRECC - VA Greater Los Angeles Healthcare System
Dr. Marder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
VA Greater Los Angeles Healthcare System, Dept. of Psychiatry
11301 Wilshire Blvd., MIRECC-210A
Los Angeles, CA 90073Phone+1 310-268-3647Fax+1 310-268-3647- Is this information wrong?
Education & Training
University of Southern California/LAC+USC Medical CenterResidency, Psychiatry, 1972 - 1975
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1971
Certifications & Licensure
CA State Medical License 1972 - 2025
MD State Medical License 1976 - 1979- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients Start of enrollment: 2000 Jun 01
- Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults Start of enrollment: 2011 Aug 01
- Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia? Start of enrollment: 2011 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic te...Spyridon Siafis, Lasse Brandt, Robert A McCutcheon, Stefan Gutwinski, Johannes Schneider-Thoma, Irene Bighelli, John M Kane, Celso Arango, René S Kahn, W Wolfgang Flei...> ;The Lancet. Psychiatry. 2024 Jan 1
- 4 citationsNegative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments.Stephen R Marder, Daniel Umbricht> ;Schizophrenia Research. 2023 Aug 1
- 1 citationsPsychosis among individuals with methamphetamine use disorder is associated with elevated rates of hospitalizations and emergency department visits across an academic ...Michael F Zito, Zhe Fei, Yuhui Zhu, Sarah E Clingan, Stephen R Marder, Larissa J Mooney> ;Journal of Substance Use and Addiction Treatment. 2023 Aug 1
- Join now to see all
Journal Articles
- Reliability and Validity of the Self-Report Version of the Apathy Evaluation Scale in First-Episode Psychosis: Concordance with the Clinical Version at Baseline and 12...Stephen Marder, MD, Psychiatry Research
Authored Content
- A Dose-Finding Study of Oxytocin Using Neurophysiological Measures of Social ProcessingJuly 2018
Press Mentions
Amyloid Fibers Reveal Themselves with near‐InfraredSeptember 3rd, 2020
FDA Approves Daily Asenapine PatchNovember 7th, 2019
Major Announcement: Schizophrenia Bulletin OpenSeptember 18th, 2019- Join now to see all
Grant Support
- Opportunities For Innovative Drug Development For SchizophreniaNational Institute Of Mental Health2009–2010
- Treatment Units For Research On Neurocognition &Schizophrenia (TURNS)National Institute Of Mental Health2007
- Relapse Prevention: Long-Acting Atypical AntipsychoticsNational Institute Of Mental Health2006
- Management For Risk Of Relapse In SchizophreniaNational Institute Of Mental Health1993–2004
- Treatment Of Negative Symptoms &Cognitive ImpairmentsNational Institute Of Mental Health2000–2003
- Core--Psychopharmacology LaboratoryNational Institute Of Mental Health1996–2000
- New Antipsychotics--Clinical Trials And FollowupNational Institute Of Mental Health1995–1997
- Predicting Optimal Neuroleptic Therapy For SchizophreniaNational Institute Of Mental Health1995
- New Antipsychotics--Use In New PopulationsNational Institute Of Mental Health1995
- Management Of Risk For Relapse In SchizophreniaNational Institute Of Mental Health1995
- Core--Psychopharmacology LaboratoryNational Institute Of Mental Health1995
- Predicting Optimal Neuroleptic Therapy For Schizophrenic OutpatientsNational Institute Of Mental Health1985–1995
- Clozapine--Treatment Response And DisabilityNational Institute Of Mental Health1992–1994
- Management Of Risk For Relapse In SchizophreniaNational Institute Of Mental Health1986–1990
Hospital Affiliations
Ronald Reagan UCLA Medical CenterLos Angeles, California
Greater Los Angeles HCSLos Angeles, California
Stewart & Lynda Resnick Neuropsychiatric Hospital at UCLALos Angeles, California- UCLA Medical Center-Santa MonicaSanta Monica, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
